Company Overview and News

Lululemon names new CFO as search for CEO continues

2018-04-17 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to:

Lululemon Names Chief Financial Officer While CEO Search Continues - Bloomberg

2018-04-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Athletic apparel maker Lululemon names Patrick Guido CFO

2018-04-16 channelnewsasia
Canadian athletic wear maker Lululemon Athletica on Monday named Patrick Guido as its chief financial officer.

Athletic apparel maker Lululemon names Patrick Guido CFO

2018-04-16 reuters
(Reuters) - Canadian athletic wear maker Lululemon Athletica (LULU.O) on Monday named Patrick Guido as its chief financial officer.

BRIEF-Lululemon Athletica Names Patrick Guido Chief Financial Officer

2018-04-16 reuters

How Lululemon Athletica (LULU) Stock Stands Out in a Strong Industry

2018-04-16 zacks
One stock that might be an intriguing choice for investors right now is Lululemon Athletica Inc. (LULU - Free Report) . This is because this security in the Textile - Apparel space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

LULU / lululemon athletica inc. PRE 14A

Document Table of Contents

Will Technology Acquisitions Power Nike Inc Stock Higher?

2018-04-11 investorplace
Over the past several years, I have closely followed the whole athletic retail competition between Nike Inc (NYSE:NKE), ADIDAS AG/S ADR (OTCMKTS:ADDYY), Under Armour Inc (NYSE:UAA), Skechers USA Inc (NYSE:SKX), and Lululemon Athletica inc. (NASDAQ:LULU).

lululemon (LULU) Up 14% YTD: Will the Bull Run Continue?

2018-04-09 zacks
lululemon athletica inc. (LULU - Free Report) continues to gain investors’ confidence backed by its 2020 Strategy, focus on e-commerce channel, global footprint expansion as well as solid top- and bottom-line surprise history. The company delivered fourth-consecutive positive earnings surprise and ninth straight sales beat in fourth-quarter fiscal 2017. This has also boosted the company’s share price performance, with the stock rallying 14.

Under Armour: Poised For Underperformance?

2018-04-09 seekingalpha
Under Armour underperformed in 2017 relative to its original expectations. They have high expectations for 2018 that will be difficult to meet given their financial situation.

Lululemon seeks new CEO with cultural fit and squeaky clean image

2018-04-09 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to:

Game Plan For The Week - Cramer's Mad Money (4/6/18)

2018-04-09 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, April 6.

Lululemon Athletica Inc. Stock Bucks the Lousy Retailing Trend

2018-04-05 investorplace
I’m not quite sure if the latest quarterly earnings from Lululemon Atheletica inc. (NASDAQ:LULU) defeats my thesis that clothing retailers are stocks to avoid, or if it is the exception that proves the rule.

7 Double-Digit Dividend Stocks for Market Safety

2018-04-04 investorplace
I happened to read an article recently about dividend increases expected in April, which got me thinking about good dividend stocks to own. Most investors view dividend stocks through the wrong lens. Typically, income investors are interested in yields of 3%-plus when they ought to be more concerned about whether a company can issue stock to consistently grow the annual dividend payout.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 550021109